What is each compound?
BPC-157
BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a sequence found in human gastric juice protein. Researchers at the University of Zagreb have studied it since the early 1990s, generating a substantial body of rodent data examining its proposed effects on nitric oxide signaling, fibroblast activity, growth factor modulation, and gastrointestinal mucosal health. No large-scale human clinical trials have been completed.
TB-500 (Thymosin Beta-4 fragment analog)
TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring 43-amino-acid protein ubiquitously expressed in human and animal tissues. Thymosin Beta-4’s biological role involves regulating actin polymerization — a fundamental process in cell motility, tissue remodeling, and cellular signaling. TB-500 is a shorter synthetic fragment believed to retain key biological activity while being more practical to produce. Like BPC-157, the preclinical literature is primarily from rodent models.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Structure | 15-amino-acid synthetic peptide | Synthetic analogue of Thymosin Beta-4 (43-aa protein) |
| Origin | Derived from human gastric juice protein sequence | Active fragment of naturally occurring TB4 protein |
| Proposed mechanism | Nitric oxide signaling, fibroblast activity, growth factor modulation | Actin regulation, cell migration, angiogenic signaling |
| Evidence base | Primarily rodent models; no large-scale human RCTs | Primarily rodent models; some early-stage human Thymosin Beta-4 research |
| US compounding status | FDA Category 2 — not permitted for 503A compounding | Not on Category 1 permitted list |
Why is the BPC-157/TB-500 blend discussed in recovery communities?
Interest in combining BPC-157 and TB-500 comes from the hypothesis that their proposed mechanisms may address different aspects of tissue recovery through complementary pathways.
BPC-157’s proposed actions include modulating nitric oxide production (which affects blood flow and vascular response), supporting fibroblast activity and collagen synthesis (key to connective tissue maintenance), and influencing growth factor expression in preclinical tissue recovery models.
TB-500’s proposed actions, through Thymosin Beta-4 pathways, include supporting actin regulation (which governs cell migration and tissue reorganization during normal repair processes) and angiogenic signaling in animal studies.
The community logic is that pairing these compounds might address vascular, connective tissue, and cellular mobility dimensions of recovery simultaneously. This is a hypothesis based on layering animal-model findings from separate studies. It has not been tested as a combined protocol in controlled human research.
Every BPC-157/TB-500 blend figure online is layered from separate rodent studies — the combination has never been tested as a protocol in humans.
What does the evidence support—and what does it not?
Both BPC-157 and TB-500 have extensive preclinical literature — hundreds of rodent studies for BPC-157, a more modest but real body of work for Thymosin Beta-4 and its analogs. The evidence from these studies is scientifically interesting enough that researchers continue pursuing it.
What that evidence does not support is making specific dosing recommendations for humans. Key gaps include:
- No human pharmacokinetic data for either compound: we do not know how much of an injected dose reaches target tissues in humans, how long it remains active, or how it distributes systemically.
- No human dose-response data: doses circulating in online discussions are extrapolated from animal studies using body-weight scaling, a methodology known to be imprecise across species for complex biologics.
- No combination-protocol data: even if we had human data for each peptide individually, combining them introduces interaction unknowns that have not been studied.
- No long-term safety data in humans: the consequences of sustained use over months or years are unknown.
What is the regulatory status of BPC-157 and TB-500 in the US?
Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is currently on FDA’s 503A Bulks List. This means:
- There is no approved product and no established clinical dose for a BPC-157/TB-500 blend, so no dosing figure has been reviewed by a regulator.
- Products offered through gray-market vendors, research chemical suppliers, or overseas websites are not manufactured under pharmaceutical-grade purity and sterility standards. Their composition, concentration, and safety cannot be verified.
- The regulatory landscape is evolving. On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review both BPC-157 and TB-500 for addition to the 503A Bulks List. Any recommendation from that committee is non-binding, and FDA has not issued a final determination.
Whether any therapy is appropriate is a clinical decision. If your recovery goals involve connective tissue, musculoskeletal support, or general tissue maintenance, the program that best fits your situation is our Recovery & Repair program, where a clinician reviews your case and identifies what is currently available through legal prescription channels.
Frequently asked questions
What is a BPC-157/TB-500 blend?
A BPC-157/TB-500 blend is a compound preparation combining two peptides: BPC-157, a 15-amino-acid synthetic peptide derived from a gastric protein sequence, and TB-500, a synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cellular signaling. The combination is discussed in recovery-focused communities on the theory that their proposed mechanisms may act through complementary pathways.
What is the regulatory status of a BPC-157/TB-500 blend in the USA?
Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is currently on FDA's 503A Bulks List. That status is in active transition: FDA's Pharmacy Compounding Advisory Committee met to review BPC-157 and TB-500 on July 23-24, 2026. Any recommendation from that committee is non-binding, and FDA has not issued a final determination.
What does the research say about dosing BPC-157 and TB-500 together?
There are no published human clinical trials establishing dosing protocols for a BPC-157/TB-500 blend. Quantities circulating in online communities are extrapolated from separate rodent studies of each peptide individually. These estimates carry significant uncertainty because animal-to-human dose extrapolation is imprecise, and no human pharmacokinetic data exists for either compound alone, let alone combined.
Why do people combine BPC-157 and TB-500?
Community interest in the blend stems from the hypothesis that BPC-157's proposed effects on nitric oxide signaling and fibroblast activity, and TB-500's proposed effects through Thymosin Beta-4 pathways and actin regulation, might address different aspects of tissue recovery in a complementary way. This remains a hypothesis from preclinical data, not a clinically validated protocol.
What are the risks of obtaining BPC-157/TB-500 blend from unregulated sources?
Obtaining either peptide from gray-market sources or research chemical vendors carries serious risks: unverified purity, absence of sterility testing, inaccurate concentrations, contamination with unknown substances, and no medical oversight. PepScribe strongly advises against obtaining any peptide from unregulated sources.
